Drug General Information
Drug ID	D07WCT
Former ID	DIB011175
Drug Name	SAR-100842
Synonyms	LPA1/LPA3 antagonist (renal fibrosis), sanofi-aventis
Indication	Fibrosis [ICD9: 709.2; ICD10:L90.5]		Phase 2	[523991]
Company	Sanofi us
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Lysophosphatidic acid receptor Edg-2	Target Info	Modulator	[544454]
	Lysophosphatidate-3 receptor	Target Info	Modulator	[544454]
KEGG Pathway	Rap1 signaling pathway
	Neuroactive ligand-receptor interaction
	PI3K-Akt signaling pathway
	Gap junction
	Pathways in cancerhsa04015:Rap1 signaling pathway
	Pathways in cancer
NetPath Pathway	TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database	LPA receptor mediated eventslysophospholipid_pathway:LPA receptor mediated events
Reactome	G alpha (q) signalling events
	G alpha (i) signalling events
	Lysosphingolipid and LPA receptorsR-HSA-416476:G alpha (q) signalling events
	Lysosphingolipid and LPA receptors
WikiPathways	Myometrial Relaxation and Contraction Pathways
	Gastrin-CREB signalling pathway via PKC and MAPK
	Small Ligand GPCRs
	GPCR ligand binding
	GPCR downstream signalingWP2664:Gastrin-CREB signalling pathway via PKC and MAPK
	GPCR downstream signaling
References
Ref 523991	ClinicalTrials.gov (NCT01651143) Proof of Biological Activity of SAR100842 in Systemic Sclerosis. U.S. National Institutes of Health.
Ref 544454	Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.